ePrints@IIScePrints@IISc Home | About | Browse | Latest Additions | Advanced Search | Contact | Help

Targeting the dopamine receptor in schizophrenia: investigational drugs in Phase III trials

Rao, Naren P and Remington, Gary (2014) Targeting the dopamine receptor in schizophrenia: investigational drugs in Phase III trials. In: EXPERT OPINION ON PHARMACOTHERAPY, 15 (3). pp. 373-383.

exp_opi_pha_15-3_373_2014_ac.pdf - Accepted Version

Download (415kB) | Preview
Official URL: http://dx.doi.org/10.1517/14656566.2014.873790


Introduction: Antipsychotic drugs date back to the 1950s and chlorpromazine. Soon after, it was established that blockade of dopamine and, in particular, the D-2 receptor was central to this effect. Dopamine continues to represent a critical line of investigation, although much of the work now focuses on its potential in other symptom domains. Areas covered: A search was carried out for investigational drugs using the key words `dopamine', `schizophrenia' and `Phase III' in an American clinical trial registry (clinicaltrials.gov), published articles using the National Library of Medicine's PubMed database, and supplemented results with a manual search of cross-references and conference abstracts. Drugs were excluded that were already FDA approved. Expert opinion: There remains interest, albeit diminished, in developing better antipsychotic compounds. The greatest enthusiasm currently centres on dopamine's role in negative and cognitive symptom domains. With theories conceptualising hypodopaminergic activity as underlying these deficits, considerable effort is focused on drug strategies that will enhance dopamine activity. Finally, a small body of research is investigating dopaminergic compounds vis-a-vis side-effect treatments. In domains beyond psychosis, however, dopamine arguably is not seen as so central, reflected in considerable research following other lines of investigation.

Item Type: Journal Article
Additional Information: Copyright for this article belongs to the INFORMA HEALTHCARE,ENGLAND
Keywords: dopamine receptor; dopaminergic; Phase III; schizophrenia
Department/Centre: Division of Biological Sciences > Centre for Neuroscience
Date Deposited: 20 Feb 2014 05:13
Last Modified: 21 Feb 2014 03:57
URI: http://eprints.iisc.ac.in/id/eprint/48410

Actions (login required)

View Item View Item